key: cord-0993310-el3c9lkj
authors: Enos, Tyler; Jeong, Haneol S.; Vandergriff, Travis; Jacobe, Heidi T.; Chong, Benjamin F.
title: Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID‐19
date: 2020-06-15
journal: Dermatol Ther
DOI: 10.1111/dth.13834
sha: 8ee21688a43b117668d6b58bf51984af834d3ec1
doc_id: 993310
cord_uid: el3c9lkj

nan

Acute generalized exanthematous pustulosis (AGEP) is a severe cutaneous adverse reaction. Rare cases secondary to hydroxychloroquine (HCQ) are documented in the literature. [1] [2] [3] [4] [5] [6] [7] [8] We report a case of a woman who developed AGEP after initiating HCQ for a presumed diagnosis of COVID-19. Results of her initial and repeat COVID-19 testing were ultimately negative. We present this case to shed light on the potentially dangerous skin toxicities associated with HCQ.

A 29-year-old woman with a history of Protein S deficiency and Stevens-Johnson syndrome due to cefaclor presented to her physician for subjective fever, cough, and sore throat. Given recent exposure to a COVID-19 positive individual, she was tested for COVID-19, and given a five-day course of oral azithromycin, doxycycline and prednisone, with no improvement. Eight days later, as her COVID-19 results were not yet available, she was started empirically on HCQ 200 milligrams twice daily. After four days of treatment, she awoke with rash on the neck and abdomen that spread to the face and extremities (Fig. 1) . She was instructed to stop HCQ and received a six-day oral methylprednisolone taper, which did not improve her rash. Her COVID-19 testing returned negative. The rash spread and pruritus was unrelenting. Twelve days after she began HCQ, she presented at an outside hospital, where she This article is protected by copyright. All rights reserved. testing.

The patient was admitted and treated conservatively with topical triamcinolone 0.1% ointment but experienced significant pruritus and additional pustule formation, necessitating one administration of IV methylprednisolone 500mg. The following morning her skin was less erythematous and she denied mucosal pain. Laboratory studies remained stable. She was transitioned to an oral prednisone taper to further treat her active but improving rash. A skin biopsy, collected prior to treatment, showed a subcorneal pustule with neutrophils and eosinophils consistent with a diagnosis of acute generalized exanthematous pustulosis (Fig. 2) .

The rash resolved with the prednisone taper after 38 days.

This article is protected by copyright. All rights reserved.

The rapid spread of COVID-19 has left healthcare providers across the world in search of treatment options to combat the virus. This case highlights a severe cutaneous adverse reaction to HCQ, which is currently being used empirically, despite a lack of evidence to support its use. 9 In classic AGEP, onset occurs within 48 hours of drug initiation, and most cases resolve within two weeks after the offending medication is stopped. 1, [4] [5] In reported cases of HCQ-induced AGEP, there is a longer latency period, ranging from 4-30 days. Additionally, the duration of the eruption may be lengthy, up to 81 days, and prolonged treatment with systemic steroids or cyclosporine may be necessary to treat the reaction. [4] [5] [6] [7] [8] It is possible that the protracted course is secondary to HCQ's long half-life. [4] [5] Our patient's presentation was likely somewhat attenuated, with fewer pustules, due to the systemic steroids she received prior to presentation. The absence of reliable, rapid COVID-19 testing contributed in this case. While HCQ is generally well-tolerated, dermatologic adverse effects can occur and may be severe.

This article is protected by copyright. All rights reserved.

Acute generalized exanthematous pustulosis (AGEP): A review and update

Acute generalized exanthematous pustulosis precipitated by hydroxychloroquine

Cyclosporine for corticosteroid-refractory acute generalized exanthematous pustulosis due to hydroxychloroquine

Prolonged pustular eruption from hydroxychloroquine: an unusual case of acute generalized exanthematous pustulosis

Acute generalized exanthematous pustulosis induced by hydroxychloroquine: a case with atypical clinical presentation

Rapid clearing of acute generalized exanthematous pustulosis after administration of ciclosporin

A case of prolonged generalized exanthematous pustulosis caused by hydroxychloroquine-literature review